Back to News
Market Impact: 0.15
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Source: GlobeNewswire
Healthcare & Biotech
Montreal Heart Institute has joined a multinational study evaluating a self-administered, repeat-dose 70 mg regimen of etripamil. The announcement signals continued clinical development activity but provides no efficacy, safety, regulatory, or financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- CorMedix stock gains as Heron deal adds four products
- Rezolute at Guggenheim: FDA progress lifts rare-disease hopes
- Hims & Hers earnings up next: Can GLP-1 boom drive profit?
- Harrow earnings on deck as investors eye profitability return